XML 71 R56.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Segment Reporting (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Segment Reporting [Abstract] |
Schedule of Reconciliation of Adjusted EBITDA to Net Loss | The following table presents our revenue, significant expenses reviewed by our CODM and net loss attributable to common shareholders of Evolent Health Inc. (in thousands):
|  |  | For the Year Ended December 31,
|  |  |  |  | 2024 |  | 2023 |  | 2022
Revenue |  |  |  |  | $2,554,741 |  | $1,963,896 |  | $1,352,013
Less: |  |  |  |  |  |  |  |  |
Medical expense and device costs |  |  |  |  | 1,813,052 |  |  | 1,143,499 |  |  | 725,036 |
Cost of revenue excluding medical expense and device costs and other segment items (1) |  |  |  |  | 369,754 |  |  | 358,265 |  |  | 304,326 |
Selling, general and administrative expenses excluding other segment items (2) |  |  |  |  | 211,475 |  |  | 267,454 |  |  | 216,320 |
Depreciation and amortization expenses |  |  |  |  | 118,370 |  |  | 123,415 |  |  | 67,195 |
Interest income |  |  |  |  | (5,544) |  |  | (5,256) |  |  | (1,369) |
Interest expense |  |  |  |  | 24,722 |  |  | 54,205 |  |  | 15,572 |
(Gain) loss from equity method investees |  |  |  |  | 3,441 |  |  | (1,290) |  |  | (4,569) |
Benefit from income taxes |  |  |  |  | (1,413) |  |  | (89,365) |  |  | (43,376) |
Change in tax receivables agreement liability |  |  |  |  | 173 |  |  | 61,982 |  |  | 45,950 |
Other segment items (3) |  |  |  |  | 114,165 |  |  | 193,247 |  |  | 46,092 |
Net loss attributable to common shareholders of Evolent Health, Inc. |  |  |  |  | $ | (93,454) |  |  | $ | (142,260) |  |  | $ | (19,164) |
———————— (1)Other segment items excluded from cost of revenue excluding medical expense and device costs include $4.6 million, $1.7 million and $4.4 million of stock compensation for the years ended December 31, 2024, 2023 and 2022, respectively, and $1.6 million of acquisition-related costs and $0.1 million of amortization of contract cost assets for the year ended December 31, 2022. (2)Other segment items excluded from selling, general and administrative expenses includes $35.2 million, $38.8 million and $29.6 million of stock compensation, $2.9 million, $1.5 million and $13.3 million of severance costs, $2.9 million, $15.1 million and $10.1 million of acquisition-related costs and $10.6 million, $35.2 million and $— million of repositioning costs for the years ended December 31, 2024, 2023 and 2022, respectively. (3)Other segment items are defined as stock-based compensation, severance costs, acquisition-related costs and repositioning costs not included in cost of revenue or selling, general and administrative expenses and income (expense) calculated in accordance with GAAP including loss on disposal of non-strategic assets, right-of-use assets impairment, loss on lease termination, change in fair value of contingent consideration, loss on extinguishment/repayment of long-term debt, net, other income (expense), net, loss from discontinued operations, net of tax and loss before preferred dividends and accretion of Series A Preferred Stock. Management believes cost of revenue excluding medical expense and device costs and other segment items and selling, general and administrative expenses excluding other segment items are useful to investors because they facilitate an understanding of our long-term operational costs while removing the effect of costs that are not a representative component of the day-to-day operating performance of our business, and are useful to management as supplemental performance measures.

X
- Definition Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration